Trial Profile

A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A in First Line Metastatic Participants

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belzutifan (Primary) ; Favezelimab/pembrolizumab (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Pembrolizumab+vibostolimab (Primary) ; Pembrolizumab/Quavonlimab (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms Substudy 03A
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

02 Oct 2025 According to Eisai Co Ltd media release, company will present data from this study in a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2025.
17 Apr 2024 Status changed from recruiting to active, no longer recruiting.
28 Apr 2023 Planned End Date changed from 16 Mar 2026 to 31 May 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com